A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma

Summary

Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  MK-1045

  Intravenous (IV) infusion

• Biological
  Rituximab

  IV infusion

• Biological
  Rituximab biosimilar

  IV infusion

• Drug
  Bendamustine

  IV infusion

• Drug
  Cyclophosphamide

  IV infusion

• Drug
  Vincristine

  IV infusion

• Drug
  Prednisone

  Per approved product label

• Drug
  Prednisolone

  Per approved product label

• Drug
  Doxorubicin Hydrochloride

  IV infusion

Locations (26)